: New strategies for respiratory syncytial virus (RSV) prevention are available and are in development, but their acceptance is crucial to their effectiveness. Objectives: This systematic review aims to summarize current quantitative and qualitative evidence regarding knowledge and attitudes relating to RSV prevention. : Six databases (PubMed, Scopus, APA PsycArticles; APA PsycInfo; CINAHL Complete; Psychology and Behavioral Sciences Collection) and two preprint repositories (medRxiv and Preprints) were searched up until 23 December 2024 (PROSPERO: CRD42024602351). : Sixty-one articles were included, focusing on vaccination for the elderly and adults at risk (n = 10) or pregnant people (n = 24, of which 8 also examined preferences for maternal vs. infant immunization) and infant immunization (n = 27, of which 16 focused on palivizumab, with 6 focusing on adherence to its monthly administration). Eighteen articles assessed attitudes in healthcare professionals. Overall, findings showed limited knowledge and awareness of RSV but generally positive attitudes towards prevention strategies and moderate to high intentions and uptake rates. Protection against the disease and perceived severity promoted acceptance, whereas concerns about side effects hindered it. Maternal vaccination was more acceptable than infant immunization. : Attitudes towards RSV prevention options were generally favorable. Should more options become available, preferences may depend on which options are available, their characteristics, and how they are framed and presented. These insights highlight the importance of education on RSV grounded in decision-making literature, while recognizing the likely favorable reception of preventive measures across target age-populations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861692 | PMC |
| http://dx.doi.org/10.3390/vaccines13020159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024.
J Infect
March 2025
Department of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia; Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, University of Western Australia, Perth, Western Australia, Australia; School of Medicine, University of Western Australia, Perth, WA, Australia; Department of Microbiology, PathWest Laboratory Medicine, Perth, Western Australia, Australia.
Background: Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
View Article and Find Full Text PDFResveratrol reduces RVLM neuron activity via activating the AMPK/Sirt3 pathway in stress-induced hypertension.
J Biol Chem
March 2025
School of Environmental and Chemical Engineering, Shanghai University, Shanghai, China; School of Life Sciences, Shanghai University, Shanghai, China; College of Life Sciences, Dezhou University, Dezhou, Shandong, China; College of Agriculture and Bioengineering, Heze University, Heze, Shandong, China; Department of Preventive Medicine, Heze Medical College, Heze, Shandong, China; Shaoxing Institute of Shanghai University, Shaoxing, Zhejiang, China. Electronic address:
Neuronal hyperexcitability in the rostral ventrolateral medulla (RVLM), driven by oxidative stress, plays a crucial role in stress-induced hypertension (SIH). While resveratrol (RSV) is known for its antioxidant properties, its effects on RVLM neurons in SIH remain unclear. We investigated this using an SIH rat model exposed to electric foot shocks and noise stimulation for 15 days.
View Article and Find Full Text PDFClinical phenotypes and outcomes associated with respiratory syncytial virus infection in critically ill patients: a retrospective multicentre cohort study in Great Paris area hospitals, 2017-2023.
J Infect Dis
March 2025
Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor - Albert Chenevier, Assistance Publique-Hôpitaux de Paris (AP-HP), 94010 Créteil, France.
Background: Respiratory syncytial virus (RSV) is one of the deadliest respiratory viruses. There is a need to better identify prognostic factors in RSV-infected patients, particularly those requiring intensive care unit (ICU) admission, with a focus on immunosuppressed patients.
Methods: Multicenter, retrospective cohort study of RSV-infected adults hospitalized in 17 ICUs in the Great Paris area between 08/01/2017 and 05/01/2023.
Epidemic patterns and the immunity levels in hospitalized patients with respiratory syncytial virus infection in 2019-2023.
J Infect Dev Ctries
February 2025
Department of Pediatrics Respiratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong University, Shandong Provincial Clinical Research Center for Children's Health and Disease office, Jinan, Shandong, 250021, China.
Introduction: The epidemic pattern of the Respiratory syncytial virus (RSV) has changed during the COVID-19 pandemic. To analyze the epidemic pattern of RSV infection and explore the fluctuations of immunity.
Methodology: Pediatric inpatients diagnosed with RSV infection or RSV pneumonia from January 2019 to August 2023 in a tertiary hospital were retrospectively included.
Genomic Characterization of RSV in the US by Vaccination Status.
JAMA
March 2025
Department of Veterans Affairs Public Health Reference Laboratory, Palo Alto, California.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!